PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 1:56 AM ET

Sponsor Check › Person

Jon Freeman

Related person on Form D filings · address states as listed: MN, MA · listed Sep 27, 2012 → Dec 6, 2023

5issuers
13Form D filings
2012–2023years listed

Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 23, 2026, 11:59 PM ET · SEC enforcement last checked: not yet

Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.

Key records

The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.

1. Lawsuits

None found in sources searched.

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:59 PM ET.

State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.

Not yet searched.

No SEC search has run yet for this person.

3. Bankruptcies

None found in sources searched.

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:59 PM ET.

State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons are made for sponsors and sponsor groups, not individual people.

5. Money to insiders and sales commissions

0 of 10 offerings report sales commissions; 0 report finder's fees; 0 report proceeds to related persons.

SourceOffering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell it
EDGAR ↗Dec 6, 2023 D
File 021-498961
$0$0$0None listed on this filing
EDGAR ↗Nov 29, 2022 D
File 021-466050
$0$0$0None listed on this filing
EDGAR ↗Nov 12, 2021 D/A
File 021-389531
$0$0$0None listed on this filing
EDGAR ↗Jun 23, 2020 D
File 021-369454
$0$0$0None listed on this filing
EDGAR ↗Mar 13, 2019 D
File 021-334701
$0$0$0None listed on this filing
EDGAR ↗Apr 24, 2017 D
File 021-285366
$0$0$0None listed on this filing
EDGAR ↗Apr 18, 2017 D/A
File 021-262438
$0$0$0None listed on this filing
EDGAR ↗Feb 13, 2017 D
File 021-280594
$0$0$0None listed on this filing
EDGAR ↗Apr 7, 2016 D/A
File 021-222927
$0$0$0None listed on this filing
EDGAR ↗Sep 27, 2012 D
File 021-184711
$0$0$0None listed on this filing

As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Appears on these filings

SourceIssuerRoleFiledFormOfferingSoldInvestorsMin. investment
EDGAR ↗Gila Therapeutics, Inc.Executive OfficerDec 6, 2023D$10,000,000
similar: $2,000,000–$19,999,994
$399,5727
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Gila Therapeutics, Inc.Executive OfficerNov 29, 2022D$5,000,000
similar: $2,000,000–$19,999,994
$355,5226
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Gila Therapeutics, Inc.Executive OfficerNov 12, 2021D/A$1,250,000
similar: $2,000,000–$19,999,994
$1,250,00028
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Gila Therapeutics, Inc.Executive OfficerFeb 16, 2021D$500,000
similar: $2,000,000–$19,999,994
$401,93417
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗OneMedNet Corp
group: Onemednet
Executive OfficerJun 23, 2020D$17,140
similar: $500,000–$7,000,000
$17,1401
similar: 2–14
No minimum reported
similar: $5,000–$50,000
EDGAR ↗Gila Therapeutics, Inc.Executive OfficerMar 13, 2019D$2,000,000
similar: $2,000,000–$19,999,994
$314,4343
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Augustine Temperature Management LLC
group: Augustine
Executive OfficerApr 24, 2017D$10,000,000
similar: $829,831–$9,999,998
$00
similar: 2–15
No minimum reported
similar: $10,000–$54,310
EDGAR ↗Gila Therapeutics, Inc.Executive OfficerApr 18, 2017D/A$4,000,000
similar: $2,000,000–$19,999,994
$3,344,88533
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Gila Therapeutics, Inc.Executive OfficerFeb 13, 2017D$500,000
similar: $2,000,000–$14,000,000
$00
similar: 1–19
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Gila Therapeutics, Inc.Executive OfficerMay 2, 2016D$3,200,000
similar: $2,000,000–$19,999,994
$2,584,72425
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗EmboMedics, Inc.Executive OfficerApr 7, 2016D/A$4,287,938
similar: $2,000,000–$19,999,994
$4,287,93829
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗EmboMedics, Inc.Executive OfficerAug 14, 2014D$5,000,000
similar: $2,000,000–$19,999,994
$846,7509
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗MEDAFOR INCExecutive OfficerSep 27, 2012D$15,000$15,0002No minimum reported

Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.

"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); Other / 506(b) (18,678 filings); Other Health Care / 506(b) (4,189 filings); Biotechnology / 506(c) (163 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Other listings under the same name

Separate person records under the same name, not combined with this page. Each line says whether it is listed on an issuer this record is also listed on (a second identifier); where it is not, it could be the same person or a different one.

  • Jon Freeman — address state CA, 6 issuers, Dec 30, 2010 → Jun 2, 2026 · no shared issuer found
  • Jon Freeman — address state NY, 1 issuer, Jan 9, 2015 → Jul 1, 2019 · no shared issuer found
  • Jon Freeman — address state MI, 1 issuer, Mar 1, 2019 → Mar 1, 2019 · no shared issuer found
  • Jon Freeman — address state FL, 1 issuer, Sep 3, 2024 → Apr 10, 2026 · no shared issuer found

Connections as of Oct 23, 2026, 5:45 PM ET

Listed alongside — 38 names on the same filings (0 management entities, 38 people)

People and management entities the issuers listed as related persons on the same Form D filings as Jon Freeman. Source: the EDGAR rows in the table above.

  • Richard Horan — 8 shared filings (1 issuer) · role as listed: Director
  • Thomas J. Vasicek — 6 shared filings (1 issuer) · roles as listed: Executive Officer, Director, Promoter
  • Christopher de Souza — 6 shared filings (1 issuer) · role as listed: Director · also listed on 1 other issuer
  • Scott Schorer — 4 shared filings (1 issuer) · roles as listed: Executive Officer, Director · also listed on 2 other issuers
  • Gerald D. Van Eeckhout — 3 shared filings (2 issuers) · role as listed: Director
  • Sergei Zolutukhin — 3 shared filings (1 issuer) · role as listed: Promoter
  • Andres Acosta — 3 shared filings (1 issuer) · role as listed: Promoter · also listed on 2 other issuers
  • Robert L. Halverson — 2 shared filings (2 issuers) · role as listed: Director
  • Timothy J. Barberich — 2 shared filings (1 issuer) · role as listed: Director · also listed on 10 other issuers
  • Kraig C. Black — 2 shared filings (2 issuers) · roles as listed: Executive Officer, Director
  • Lihui Weng — 2 shared filings (1 issuer) · role as listed: Executive Officer
  • Omid Souresrafil — 2 shared filings (1 issuer) · roles as listed: Executive Officer, Director, Promoter
  • Jafar Golzarian — 2 shared filings (1 issuer) · roles as listed: Executive Officer, Director, Promoter
  • Reza Malek — 2 shared filings (1 issuer) · role as listed: Director
  • Christopher DeSouza — 2 shared filings (1 issuer) · role as listed: Director
  • Gerald Mattys — 1 shared filing (1 issuer) · role as listed: Director · also listed on 3 other issuers
  • Michael F. Pasquale — 1 shared filing (1 issuer) · role as listed: Director
  • Paul A. Gray — 1 shared filing (1 issuer) · role as listed: Director
  • Gary J. Shope — 1 shared filing (1 issuer) · roles as listed: Executive Officer, Director
  • Scott Augustine — 1 shared filing (1 issuer) · roles as listed: Executive Officer, Director · also listed on 1 other issuer
  • J. Randall Benham — 1 shared filing (1 issuer) · role as listed: Executive Officer · also listed on 1 other issuer
  • Robert Stevens — 1 shared filing (1 issuer) · role as listed: Director · also listed on 5 other issuers
  • Brent Augustine — 1 shared filing (1 issuer) · roles as listed: Executive Officer, Director · also listed on 1 other issuer
  • R. Andreas Deibel — 1 shared filing (1 issuer) · role as listed: Executive Officer
  • JERRY HIATT — 1 shared filing (1 issuer) · role as listed: Director
  • Dr. Craig B. Wisman — 1 shared filing (1 issuer) · role as listed: Executive Officer
  • Susan Augustine — 1 shared filing (1 issuer) · role as listed: Director · also listed on 1 other issuer
  • Garrett Augustine — 1 shared filing (1 issuer) · roles as listed: Executive Officer, Director · also listed on 1 other issuer
  • Michael R. Cardenas — 1 shared filing (1 issuer) · role as listed: Promoter
  • JEFFREY YU — 1 shared filing (1 issuer) · role as listed: Director · also listed on 1 other issuer
  • John Keating — 1 shared filing (1 issuer) · role as listed: Director
  • THOMAS KOSASA — 1 shared filing (1 issuer) · role as listed: Director · also listed on 1 other issuer
  • ERKAN AKYUZ — 1 shared filing (1 issuer) · role as listed: Director · also listed on 1 other issuer
  • MIKE LACHANCE — 1 shared filing (1 issuer) · role as listed: Executive Officer
  • Tom Vasicek — 1 shared filing (1 issuer) · role as listed: Executive Officer
  • Praveen Tyle — 1 shared filing (1 issuer) · role as listed: Director
  • Sangeeta Kashyap — 1 shared filing (1 issuer) · role as listed: Executive Officer
  • Mark Kravik — 1 shared filing (1 issuer) · role as listed: Director · also listed on 1 other issuer

Other offering types (Regulation A and Regulation Crowdfunding)

None found in sources searched.

Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.

Export this report as PDF (members · included free during the launch period)

Change history

No corrections have been requested for this page.

Facts from public records only, each linked to its source. No ratings, no opinions. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Jon Freeman appears on a new Form D, or when a court case or SEC action is matched to them. See plans →